News & Events
Genetic Analysis Announces First Australian Placement of the GA-map® Dysbiosis Test at Centre for Digestive Diseases in Sydney (opens in a new tab)
Oslo, Norway / Sydney, Australia – 21.08.2026: Genetic Analysis AS (GA), a leader in microbiome diagnostics and developer of the GA-map® Dysbiosis Test, today announces the launch of its technology at the Centre for Digestive Diseases (CDD) in Sydney, Australia. The implementation marks the first placement of GA’s micr…
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs (opens in a new tab)
Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK) IST data support SER-155 as a…
Genetic Analysis demonstrates global applicability of the GA-map® Dysbiosis Test in a peer-reviewed publication (opens in a new tab)
OSLO, NORWAY – 16 July 2026: Genetic Analysis AS (“GA” or “the Company”) announces today the publication of a peer-reviewed study in the renowned scientific journal Gut Microbes. The publication demonstrates that the GA-map® Dysbiosis Test delivers consistent results across geographically diverse populations. These fin…
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment (opens in a new tab)
80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK) SER-155 has potential to treat irEC, a frequent side effect of immune…
July 6, 2026: MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract (opens in a new tab)
MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract   Lyon, France, July 6, 2026 – 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem …
June 26, 2026: MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease (opens in a new tab)
MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional Marketing Authorization Appl…
pharmaphorum – Is women’s health reaching an inflection point? (opens in a new tab)
View article…
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (opens in a new tab)
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune…
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 (opens in a new tab)
Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability Clinical data from investigator-sponsored…
Publication of interim report January – March 2026 (opens in a new tab)
OSLO, NORWAY – May 28, 2026: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the interim report for the period January – March 2026. The report is available as an attached file to this release and on the Company’s website. Below is a summary of the report. Ronny Hermansen, CEO of Genetic Analysis, comments…
May 26, 2026: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026 (opens in a new tab)
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026 MaaT013 (Xervyteg®): In May 2026, the Company was informed of a “negative trend” opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agenc…
In Vivo – The Wonders Of The Microbiome Approach According To Freya Biosciences (opens in a new tab)
View article…
Minutes of Annual General Meeting (opens in a new tab)
The post Minutes of Annual General Meeting appeared first on Genetic Analysis .…
May 20, 2026: MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease (opens in a new tab)
MaaT Pharma Announces Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease During the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) Oral Explanation, the Company received a “negative tr…
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference (opens in a new tab)
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference and will present a company overview at 3:30 p.m.…
May 11, 2026: MaaT Pharma to Hold Annual General Meeting on June 16, 2026 (opens in a new tab)
MaaT Pharma to Hold Annual General Meeting on June 16, 2026 Lyon, France, May 11, 2026 – 6:00pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer th…
Genetic Analysis granted a U.S. patent for companion diagnostic related to IBS treatment response (opens in a new tab)
OSLO, NORWAY – 7 May 2026: Genetic Analysis AS (“GA” or “the Company”) announces today the United States Patent And Trademark Office (USPTO) has granted U.S. patent no. 12,596,121, titled “COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECAL MICROBIOTA TR…
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (opens in a new tab)
Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biotherapeutic programs in inflammatory and immune diseases Company pursuing partnerships and other…
Genetic Analysis AS publishes Annual Report 2025 (opens in a new tab)
OSLO, NORWAY – 4 May 2026: Genetic Analysis AS (the “Company”, Ticker: GEAN) hereby publishes the Annual Report for the financial year of 2025. The Annual Report is available as an attached file to this release and on the Company’s website (www.genetic-analysis.com). For further information, please contact: Ronny Herma…
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease (opens in a new tab)
Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform response to biologics and patient stratification Presentation selected for DDW…